Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.

GI bleeding a potential complication of direct anticoagulant use in atrial fibrillation

27 Nov 2020
The story of warfarin: From cattle killer to rat poison to humanity’s most cherished drug

Atrial fibrillation (AF) patients receiving direct oral anticoagulants (DOACs) may be at risk of gastrointestinal (GI) bleeding, a recent study has found. This must be taken into consideration when prescribing anticoagulants, particularly to elderly patients.

Researchers conducted a retrospective cohort study including 1,086 AF patients (median age, 73 years; 67.6 percent male), with a special focus on the very elderly (n=112). Most of the participants were prescribed DOAC doses in agreement with existing guidelines, while around a third were underdosed.

Over a total observation period of 2,467.3 patient-years, 112 bleeding events at any site were reported. The resulting incidence rate was 4.5 per 100 person-years. GI bleeding accounted for more than half of the cases (n=66), with an incidence rate of 2.7 per 100 person-years.

Intracranial bleeding was reported in nine patients (0.4 per 100 person-years), while the remaining 37 cases occurred across various sites. Major adverse cardiac and cardiovascular events (MACCEs) occurred in 110 patients, yielding an incidence rate of 4.7 per 100 person-years.

Cox proportional hazards analysis found that being ≥85 years of age was a significant risk factor for all bleeding events (adjusted hazard ratio [HR], 2.15, 95 percent confidence interval [CI], 1.29–3.58; p=0.003), particularly GI bleeding (adjusted HR, 2.256; 95 percent CI, 1.165–4.366; p=0.016).

Other important risk factors for bleeding included chronic kidney disease and being medicated with low-dose aspirin or nonsteroidal anti-inflammatory drugs.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 21 Dec 2020
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Elaine Soliven, 12 Dec 2020
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Pearl Toh, 15 Dec 2020
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Roshini Claire Anthony, 21 Dec 2020

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.